**About the Editors**

**G ´abor J. Szebeni**, Ph.D. Dr. Szebeni studied the tumor microenvironment at the University of Szeged and Biological Research Centre in Szeged and received his Ph.D. in 2012. Briefly, he contributed to the dissection of T-cell apoptosis caused by tumor-derived galectin-1, and he showed the tumor-promoting effect of mesenchymal stem cell derived galectin-1. In order to work on cancer-related inflammation, he joined Prof. Antonio Sica's group in Milan as a postdoctoral fellow. They revealed the role of RorC1 in the cancer-driven emergency granulo-monocytopoiesis. Afterward, he worked on the investigation and development of anti-cancer therapeutics as a project leader at Avidin Ltd. He gave university lessons about 'Milestones in Cancer'. He successfully implemented the first mass cytometer in Hungary and currently leads the cytometry unit at the Biological Research Centre in Szeged, focusing on the dysregulation of immune homeostasis in human pathologies such as autoimmunity (RA, SLE, SSC), cancer (adenocarcinoma, breast cancer, AML), and inflammation (obesity, colitis, COPD).

**L ´aszl ´o G. Pusk ´as**, Ph.D., D.Sc. Dr. Puskas received a Degree in Biology (1994) and a Ph.D. ´ in Chemistry (1997) at the Medical Faculty of the University of Szeged, Hungary. He received his D.Sc. in Biology from the Hungarian Academy of Sciences (2006). He was a postdoctoral fellow in the field of biotechnology at Research Institute of Innovative Technology for the Earth (RITE), Kyoto, Japan, and was a guest researcher at the Microarray Facility, Leuven, Belgium. He has been the head of the Laboratory for Functional Genomics in the Biological Research Centre in Szeged, Hungary, since 1999. He became the scientific advisor and later the chief executive officer of Avidin Ltd., the chief executive officer of Avicor Ltd, and the chief executive officer of Aperus Pharma Co. Ltd. He is the author of more than 170 scientific papers and the main investigator of 13 patents. His main scientific contributions are the discovery and development of Q134R, a multitarget clinical candidate against Alzheimer's disease, and the development of single-cell digital RNA profiling and chemical microarray technologies.
